Results 141 to 150 of about 37,814 (299)

Acute anterior uveitis following intravitreal bevacizumab but not subsequent ranibizumab

open access: yesClinical Ophthalmology, 2011
Christina Antonopoulos1, Maxwell Stem2, Grant M Comer21Department of Ophthalmology, Boston University, Boston, MA, USA; 2WK Kellogg Eye Center, Department of Ophthalmology, University of Michigan, Ann Arbor, MI, USAPurpose: Previous reports have ...
Antonopoulos C, Stem M, Comer GM
doaj  

Visual Performance in Patients with Neovascular Age-Related Macular Degeneration Undergoing Treatment with Intravitreal Ranibizumab [PDF]

open access: yes, 2013
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Purpose.
Beatty, S   +6 more
core   +3 more sources

Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeys.

open access: yesPLoS ONE, 2014
PurposeIt is known that endothelial cells in the kidney are also strongly VEGF-dependent. Whether intravitreal drugs can be detected within the glomeruli or affect VEGF in glomerular podocytes is not known.
Alexander Tschulakow   +5 more
doaj   +1 more source

Factors influencing clinical outcomes in patients with diabetic macular edema treated with intravitreal ranibizumab: comparison between responder and non-responder cases

open access: yesScientific Reports, 2019
Diabetic macular edema (DME) is the leading cause of visual impairment in patients with diabetes mellitus. A retrospective study was conducted to investigate the factors influencing the clinical outcomes in 73 patients (94 eyes) with DME treated with ...
Yen-Po Chen   +3 more
semanticscholar   +1 more source

Characterization of Biodegradable Microsphere-Hydrogel Ocular Drug Delivery System for Controlled and Extended Release of Ranibizumab

open access: yesTranslational Vision Science & Technology, 2019
Purpose To characterize a biodegradable microsphere-hydrogel drug delivery system (DDS) for controlled and extended release of ranibizumab. Methods The degradable microsphere-hydrogel DDSs were fabricated by suspending ranibizumab-loaded or blank poly ...
Wenqiang Liu   +4 more
semanticscholar   +1 more source

A pilot study of intralesional ranibizumab on pterygium vascularity, size and recurrence rate [PDF]

open access: yes, 2015
Introduction: Pterygium is a common eye disorder in Malaysia due to the country’s location near to the equator. Recent study has found that vascular endothelial growth factor (VEGF) is present in great amount in pterygium epithelium especially in its ...
Chi, Ho Hao
core  

Profile of ranibizumab: efficacy and safety for the treatment of wet age-related macular degeneration

open access: yesTherapeutics and Clinical Risk Management, 2012
Youxin Chen, Fei HanDepartment of Ophthalmology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, ChinaAbstract: Wet age-related macular degeneration (AMD) causes severe vision loss due
Chen Y, Han F
doaj  

EFEKTIVITAS-BIAYA PENGGUNAAN BEVACIZUMAB DAN RANIBIZUMAB SEBAGAI ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR PADA PASIEN DENGAN GANGGUAN MATA: TINJAUAN SISTEMATIS

open access: yesKartika: Jurnal Ilmiah Farmasi
Anti-vascular endothelial growth factor (VEGF) injeksi intravitreal dapat digunakan untuk terapi pasien dengan gangguan mata. Obat anti-VEGF yang digunakan di antaranya bevacizumab, ranibizumab, aflibercept, dan brolucizumab.
Nur Sidik Cahyono   +1 more
doaj   +1 more source

Home - About - Disclaimer - Privacy